The two GLP-1 heavyweights, head to head. Same family, different firepower.
Bottom line: Tirzepatide produces more weight loss in virtually every head-to-head comparison — about 20% vs 14% at similar timepoints. Side effect profiles are comparable. Semaglutide has more years of safety data and an oral pill option. Most people choosing between these two are really choosing between 'good enough with more data' and 'best results available right now.'
| Semaglutide | Tirzepatide | |
|---|---|---|
| Category | GLP-1 receptor agonist | Dual GLP-1/GIP receptor agonist |
| Mechanism | Activates GLP-1 receptors to reduce appetite and slow gastric emptying | Activates both GLP-1 and GIP receptors for a two-pronged hit on appetite, insulin, and fat storage |
| Reported dose | 0.25 mg up to 2.4 mg weekly (injection); 3–25 mg daily (oral) | 2.5 mg up to 15 mg weekly (injection) |
| Frequency | Once weekly (injection) or once daily (oral) | Once weekly (injection) |
| Weight loss (trials) | ~14–15% body weight at 68 weeks (STEP trials, 2.4 mg) | ~20–22% body weight at 72 weeks (SURMOUNT trials, 15 mg) |
| Top side effect | Nausea (affects ~37% of users, worst during dose increases) | Nausea (similar rates, plus some diarrhea — GI symptoms fade after titration) |
| Evidence tier | Tier 1 — massive RCT base, FDA-approved for diabetes and obesity | Tier 1 — large RCTs, FDA-approved for diabetes and obesity |
| Common vial size | 5 mg or 10 mg vials (compounded); branded pens are pre-filled | 5 mg, 10 mg, 15 mg vials (compounded); branded pens pre-filled |
| Approval status | FDA-approved as Ozempic (diabetes), Wegovy (weight loss), Rybelsus (oral) | FDA-approved as Mounjaro (diabetes), Zepbound (weight loss) |
Semaglutide makes sense if you want the most studied GLP-1 on the planet, need an oral option (no injections), or your insurance covers Ozempic/Wegovy but not Mounjaro/Zepbound. It is also available in more markets globally.
Tirzepatide is the move when maximizing weight loss matters most. The dual-agonist mechanism consistently beats semaglutide by 5–7 percentage points in trials. If you have plateaued on semaglutide or want stronger results from the start, tirz is the upgrade.
Tirzepatide produces more weight loss in virtually every head-to-head comparison — about 20% vs 14% at similar timepoints. Side effect profiles are comparable. Semaglutide has more years of safety data and an oral pill option. Most people choosing between these two are really choosing between 'good enough with more data' and 'best results available right now.'
← Browse all peptides | All comparisons →
vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify